HCT 116-I6 Invasive Cell Line
Invented at Queen's University Belfast
- Datasheet
- References (4)
- Inventor Info
Info
| Catalogue Number | 153208 |
| Parental Line | HCT 116 |
| Host | Human |
| Tissue | Colon |
| Disease Keywords | Colorectal cancer |
| Model | Cancer Model |
| Relevance | The HCT 116-I6 cell line is a sub-line of HCT 116 that demonstrates a 4- and 20-fold increase in migration and invasion rate respectively compared to the parental cell line. The increased migratory/invasion capacity seen in HCT116-I6 cells is a stable event and not due to increased proliferation rates. |
| Production Details | HCT 116 cells were incubated in a Matrigel Invasion Chambers (MIC) for 72-96h. The cells that invaded through to the bottom chamber were collected and designated as ‘Invasive 1’ (I1). These cells were propagated and repeatedly passed through the MIC until highly invasive HCT116-I6 cells were selected. |
| Conditional | No |
| Research Area | Cancer, Cell Structure and Motility, Drug Discovery & Development |
| Growth/Phenotype Keywords | Invasion, migration |
| Recommended Growing Conditions | McCoy’s 5a Medium (GIBCO # 16600) + 10% FBS + 100 units/ml penicillin+ 100 μg/ml streptomycin |
| Cellosaurus ID | CVCL_HG06 |
References: 4 entries
Dunne et al. 2016. Clin Cancer Res. 22(1):230-42. PMID: 26283684.
EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.
Europe PMC ID: 26283684
Dunne et al. 2014. Clin Cancer Res. 20(1):164-75. PMID: 24170546.
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Europe PMC ID: 24170546
Add a reference
References: 4 entries
Dunne et al. 2016. Clin Cancer Res. 22(1):230-42. PMID: 26283684.
EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.
Dunne et al. 2014. Clin Cancer Res. 20(1):164-75. PMID: 24170546.
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Add a reference
